Stocks · News reference

NewcelX Announces Publication Of Peer-Reviewed Study On The Potential Of AstroRx, A Human Embryonic Stem Cells-Derived Astrocyte Therapy, In The Journal Stem Cell Reports

Jun 15, 2026, 12:34 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
AKAN BYSI CAPR CBUS ETON
BenzingaJul 31, 2026, 1:01 PMBenzinga Newsdesk
NewcelX Announces Private Placement Of 347,134 Shares At $4.033 Per Share
NCEL
BenzingaJul 15, 2026, 1:01 PMBenzinga Newsdesk
NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent
NCEL
BenzingaJul 13, 2026, 11:28 AMBenzinga Newsdesk
Laidlaw & Co. Initiates Coverage On NewcelX with Buy Rating, Announces Price Target of $23
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating and announces Price Target of $23.
NCEL